Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT extension long-term safety follow-up of teplizumab
2020-002798-92Phase 3Active
- Sponsor
- Provention Bio
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teplizumab in diabetes mellitus type 1 (T1D), sponsored by Provention Bio. Primary endpoint: Incidence of adverse events and serious adverse events. Started Feb 2021; status: active.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2020-002798-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002798-92.